Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10124181 | 0.94 | CRHR1 (0.37) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13085179 | 0.93 | CRHR1 (0.38) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL685487 | 0.93 | CRHR1 (0.38) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13084993 | 0.92 | CRHR1 (0.38) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13084961 | 0.92 | CRHR1 (0.38) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13085104 | 0.92 | CRHR1 (0.38) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL10124152 | 0.91 | DHODH (0.32) | — | |
| SCHEMBL10075531 | 0.90 | CRHR1 (0.37) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13085091 | 0.90 | CRHR1 (0.36) | CRHR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13085060 | 0.90 | CRHR1 (0.36) | CRHR1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790202-B2 | Anthranilamide derivatives as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-10-17 | — | — | US | disclosed |
| US-9790202-B2 | Anthranilamide derivatives as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-10-17 | — | — | US | disclosed |
| US-20120010250-A1 | Anthranilamide derivatives as pesticides | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010250-A1 | Anthranilamide derivatives as pesticides | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010250-A1 | Anthranilamide derivatives as pesticides | ANTXR2, NQO2, AADAC | CRHR1 3796/4885MAPK14 3140/4885MAPK13 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.